Key Takeaways
- Unique Pharmaceutical Laboratories is voluntarily recalling its generic cetirizine hydrochloride tablets (the active ingredient in Zyrtec) due to possible cross‑contamination with ranitidine, a heartburn medication.
- The recall affects 100‑tablet bottles distributed nationwide by Rising Pharma Holdings Inc.; the implicated lot numbers are GY825029, GY825030, GY825031, and GY825032, all with an October 2028 expiration date.
- A pharmacy technician first noticed irregular tablets—some bearing a red dot and others discolored—while counting and bottling the medication, prompting the investigation.
- The FDA warns that individuals hypersensitive to ranitidine could suffer severe reactions such as hypotension, shortness of breath, difficulty swallowing, loss of consciousness, or other life‑threatening events if they ingest the contaminated tablets.
- To date, no adverse events have been reported in connection with this recall.
- Consumers who possess the recalled product should stop using it, contact Rising Pharma Holdings for return instructions, and consult a healthcare provider if they experience any unusual symptoms.
- Rising Pharma Holdings has set up a dedicated phone line (1‑844‑874‑7464) and two email addresses ([email protected] and [email protected]) for questions and to arrange the return of the affected medication.
On July 18, 2025, Unique Pharmaceutical Laboratories announced a voluntary recall of its generic cetirizine hydrochloride tablets, which are marketed as a store‑brand equivalent of the allergy medication Zyrtec. The recall was initiated after a pharmacy technician observed atypical tablets while performing routine counting and bottling duties. Specifically, the technician noted that some tablets bore a red dot, while others displayed discoloration—visual cues that suggested a possible manufacturing anomaly. Concerned about the integrity of the product, the technician reported the findings, prompting the company to launch an internal investigation that ultimately pointed to potential cross‑contamination with ranitidine, a medication commonly used to treat heartburn and acid reflux.
The U.S. Food and Drug Administration (FDA) issued a recall notice detailing the scope of the issue. According to the notice, the affected product consists of cetirizine hydrochloride tablets USP 5 mg, packaged in 100‑tablet bottles. These bottles were distributed to retailers across the United States by Rising Pharma Holdings Inc., the company responsible for bringing the generic to market. The recall specifically targets four lot numbers: GY825029, GY825030, GY825031, and GY825032. All of the implicated lots share an expiration date of October 2028, meaning that the potentially contaminated medication could remain on pharmacy shelves or in consumers’ homes for several years if not removed.
The FDA’s communication emphasizes the health risk posed by the possible presence of ranitidine in the antihistamine tablets. Ranitidine, which has been the subject of its own safety reviews in recent years, can trigger severe allergic‑type reactions in individuals who are hypersensitive to the drug. Potential adverse effects include a sudden drop in blood pressure (hypotension), shortness of breath, difficulty swallowing, loss of consciousness, and other life‑threatening symptoms. While the severity of these reactions underscores the importance of the recall, the FDA also noted that, as of the recall announcement, there have been no reported cases of illness or injury linked to the contaminated tablets.
In response to the situation, Rising Pharma Holdings has taken several steps to mitigate risk and facilitate the removal of the affected product from the supply chain. The company has directly notified its wholesale and retail customers about the recall, providing clear instructions for quarantining and returning the implicated bottles. For consumers who may have purchased the medication, Rising Pharma Holdings has established a dedicated hotline (1‑844‑874‑7464) and two email addresses—[email protected] and [email protected]—through which individuals can ask questions, verify whether their product is affected, and arrange for its return or disposal. The company also advises anyone who suspects they have ingested the recalled tablets and experiences any unusual symptoms to seek immediate medical attention and inform their healthcare provider about the potential exposure.
The recall underscores the importance of vigilant quality control throughout the pharmaceutical manufacturing and distribution process. The initial detection by a pharmacy technician—based on simple visual inspection—demonstrates how frontline staff can play a critical role in identifying potential safety issues before they reach patients. While the lack of adverse event reports to date is reassuring, the FDA and the companies involved are treating the situation with the utmost seriousness, given the possible severity of reactions to ranitidine contamination.
In summary, the recall of generic cetirizine hydrochloride tablets due to possible ranitidine cross‑contamination is a precautionary measure aimed at protecting consumers with sensitivities to the heartburn drug. The affected lots—GY825029 through GY825032, packaged in 100‑tablet bottles with an October 2028 expiration—are being withdrawn from the market, and consumers are urged to discontinue use, contact Rising Pharma Holdings for return instructions, and consult a healthcare provider if they develop any concerning symptoms. No injuries have been reported thus far, but the proactive recall reflects a commitment to patient safety and rapid response to potential drug quality concerns.